Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …

Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad in
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …

Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only
antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 …

Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …

Dear Editor, Omicron (B. 1.1. 529), is a heavily mutated and highly contagious SARS-CoV-2
variant, which is currently causing large outbreaks in many countries. Protection provided by …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …